Kornimate/medical-research-clean huggingface dataset:
laser versus physiotherapy in management of bruxism in children: rcs

Conditions: Bruxism

Summary: the goal of this randomized controlled study is to compare laser acupuncture versus modified physical therapy in controlling bruxism in children. the main questions aim to answer are: * laser will decrease tempro-mandibular joint pain from bruxism more than modified physical therapy? * laser will decrease muscles activity from bruxism more than modified physical therapy? children took 6 sessions of either laser acupuncture or modified physical therapy researchers compared laser acupuncture versus modified physical therapy to see if any decrease in tempro-mandibular joint pain and muscles activity from bruxism

the children participated in the study as bruxers according to the american association of sleep medicine (aasm) diagnostic criteria \[ sixteen children will be randomly allocated to two groups of 8 individuals each: group one: laser acupuncture, group two: electromyography biofeedback training. pain will be measured by visual analogue scale; vas (primary outcome)and muscle activity will be measured by electromyography (secondary outcome) of temporalis and masseter muscles. measurements will be taken preoperatively and after 8 weeks.

Eligibility criteria:
inclusion criteria: 1. six to twelve years children 2. medically free 3. normal occlusion 4. no or low caries experience 5. clinical dental wear 6. clenching or grinding reported by the parents exclusion criteria: 1. children with any physical or psychological disease. 2. children received any previous treatment for bruxism. 3. children with tempro-mandibular joint disorders

Keywords: bruxism laser children physiotherapy
efficiency of intercoat (oxiplex/ap gel)in decreasing intrauterine adhesions

Conditions: Asherman Syndrome

Summary: this is a prospective single blind randomized controlled pilot study was designed to investigate whether the biological barrier intercoat (oxiplex/ap gel) reduces formation of intrauterine adhesions following hysteroscopic treatment for retained products of conception.

thirty women randomly divided equally into those who received intercoat following hysteroscopic treatment for retained products of conception (study group) and those who did not receive the gel (controls). safety and efficacy of the preparation were evaluated.

Eligibility criteria:
inclusion criteria: * age between 18 and 50 years * availability of the results of vaginal ultrasound or diagnostic hysteroscopy exclusion criteria: * signs of infection upon admission * ongoing pregnancy

Keywords: oxiplex/ap gel prevention of asherman's syndrome intra uterine adhesions
acute local metabolomic alterations in blood and muscle tissue in intermittent claudication

Conditions: Peripheral Arterial Occlusive Disease Fontaine Stage IIa

Summary: the most common clinical presentation of lower extremity arterial disease is intermittent claudication. current understanding of the pathophysiology of intermittent claudication, as well as its treatment options are limited. the progression of the disease may lead to lower limb amputation, which is devastating for patients' quality of life and is a huge socio-economic burden to society. current study allows to determine the acute local metabolomic alterations in the ischaemic limb of the patient with intermittent claudication, and investigate the associations between the metabolomic alterations and the patient's maximal walking distance. this provides potentially valuable insight into the pathophysiology of this disease, and helps lay the groundwork for identifying potential novel targets for instituting more effective therapies for this high-risk population.


Eligibility criteria:
inclusion criteria: * lead group: patients with diagnosis of lower extremity arterial disease (fontaine iia). * control group: healthy volunteers with no leg symptoms and an ankle-brachial index (abi) of 1.0-1.4. exclusion criteria: * fontaine stages i or iib-iv * exacerbation of limb ischaemia within the preceding 2 weeks; * strong rest pain of any cause; * age \ 80 years; * fasting \< 6 hours; * time since last use of tobacco products \< 6 hours; * body mass index ≥ 35 kg/m2 * poor sonographic visibility of femoral artery; * angina; * cardiac arrhythmia at the time of presentation; * presence of cardiac pacemaker; * myocardial infarction within the preceding 3 months; * stroke within the preceding 6 months; * ongoing anticoagulant therapy; * ongoing dual antiplatelet therapy; * any revascularization within the preceding 3 month; * marked heart failure (nyha iii-iv); * blood pressure ≥ 180/110 mmhg; * blood pressure \<100/70 mmhg; * clinically significant heart valve disease; * acute infectious disease; * active malignancy or chemotherapy or disease-free \< 5 years; * type i diabetes or insulin therapy; * other clinically significant and untreated endocrine disorders; * moderate to severe bronchial asthma (gina 2016); * severe chronic obstructive pulmonary disease (mmrc grade 3-4); * acute (kdigo 2012) or chronic renal disease (egfr-epi \<30ml/min/1.73 m2); * acute or chronic liver disease; * anemia (\<110 g/l); * neuroinflammatory or neurodegenerative disease; * active rheumatism; * other diseases and factors that markedly hinder the subject's ability to walk during the treadmill exercise. * for control group exclusively: history of lower extremity arterial disease / abi \ 1.4.

Keywords: lower extremity arterial disease peripheral artery disease intermittent claudication local metabolism metabolomics arteriovenous gradients biomarkers inflammation ischemia-reperfusion injury
human iggs and endothelial function in vivo in humans

Conditions: Common Variable Immunodeficiency

Summary: endothelial dysfunction and insulin resistance play a key role in the onset and development of atherosclerosis, cardiovascular diseases, and diabetes. data in mice models have recently demonstrated that circulating immunoglobulins g (igg) could be involved in the process. patients with common variable immunodeficiency (cvid), who are characterized by low circulating levels of igg, might represent an ideal model to clarify the role played in vivo in humans by circulating igg. polyclonal igg, obtained from multiple donors, given intravenously (ivigg), are used to treat various immunodeficiencies and autoimmune diseases, including cvid. by using this disease and its treatment by ivigg as a model, aim of the current study is to clarify whether igg affect endothelial function and insulin sensitivity in humans in vivo and whether the action of igg on the endothelium involves a direct interaction with the endothelial cells.

for this purposes, 24 patients with cvid, receiving the last therapeutic dose of ivigg infusion 5-weeks before the baseline measurements (cvid-ivigg group), are studied. in all subjects, endothelial function is evaluated as flow mediated dilation (fmd) of the brachial artery, measured by ultrasonographic technique at baseline and 1, 7, 14, and 21 days after ivigg infusion. fmd is also measured in a group of ivigg naive cvid patients (number of patients recruited depending on availability) and a group of control healthy subjects. the latter fmd measurements serve only as a mere reference of pathological or normal values in condition of deficiency or normal levels of circulating igg and are not used for primary outcome evaluation. to dissect further the mechanisms of improved endothelial function after ivigg infusion, we investigate the role of human igg on the production of nitric oxide (no) in vitro on human coronary artery endothelial cells (hcaec) isolated from normal human coronary arteries.

Eligibility criteria:
inclusion criteria: * common variable immunodeficiency exclusion criteria: * cancer, liver cirrhosis, recent acute myocardial infarction, treatment with nitroderivates, reynaud syndrome, heart failure
steroid-eluting stent implant for the treatment of radiation-related sinusitis

Conditions: Radiation-Induced Mucositis

Summary: sinusitis is one of the most common sequelae after radiotherapy among nasopharyngeal carcinoma patients. while local steroids have been shown to be effective in the management of patients with chronic rhinosinusitis, their role in treating radiation-related sinusitis is ambiguous. poor adherence to nasal steroid spray often contributes to the failure of symptom relief. the aim of this study is to determine if steroids stents implantation into the sinuses could improve patient outcomes in radiation-related sinusitis.

investigators aim to assess the efficacy and safety of steroid-eluting stents when implanted in sinus in patients with radiation-related sinusitis. this phase iii randomized controlled study enrolled nasopharyngeal carcinoma patients who received radiotherapy and developed severe radiation-related sinusitis. subjects were randomly assigned to receive steroid-eluting stents implantation or nasal steroid spray. all study patients also received saline rinses.

Eligibility criteria:
inclusion criteria: * pathologically confirmed nasopharyngeal carcinoma patients * finished radical radiotherapy (≥66gy) for at least 3 months * tumor complete response * received appropriate medical treatment for sinusitis during or after radiotherapy * confirmed sinusitis according to european position paper on rhinosinusitis and nasal polyps 2020 * snot-22 ≥ 20 and mri lund-mackay score \> 8 * 18-70 years old exclusion criteria: * anatomic variation resulted in occluded ostiomeatal complex * karnofsky score ≤ 70 * life-threatening medical conditions * tumour residue or recurrence * acute bacterial sinusitis or acute fungal sinusitis * cystic fibrosis or primary ciliary dyskinesia * dependence on prolonged corticosteroid therapy for comorbid conditions * history of allergy to topical steroids * pregnant or breastfeeding

Keywords: nasopharyngeal carcinoma radiation-related sinusitis steroid-eluting stent
correlation between circulating tumour markers early variations and clinical response in first line treatment of metastatic colorectal cancer

Conditions: Circulating Markers; Metastatic Colorectal Cancer

Summary: the chemotherapy monitoring is currently based on radiological (recist 1.1 guideline) and clinical evaluation every 3 months. circulating markers as carcino embryonic antigen (cea), circulating tumour dna and total cell free dna represent an alternative approach to evaluate the response. in the field of metastatic colorectal cancer (mcrc) recent studies suggest that early evaluation could be clinically relevant. indeed, early tumoral response seems to be correlated to overall survival. moreover, post-operative morbidity increases with the number of prior chemotherapy treatments. early evaluation could allow to modify chemotherapy regimens when response appears to be insufficient. the aim of the present study is to evaluate, in a prospective cohort of patients treated with systemic iv chemotherapy (5 fluorouracil +/- oxaliplatin +/- irinotecan) +/- targeted therapy as first line treatment for a mcrc, the correlation between early variations of circulating tumour markers including cea, circulating tumour dna and total cell free dna, and the 3 months objective response as defined in the recist 1.1 guideline.


Eligibility criteria:
inclusion criteria: * male or female, age superior to 18 years. * histologically confirmed metastatic colorectal adenocarcinoma. * measurable disease according to the recist 1.1 guideline * ecog performance status \<3. * disease requiring iv chemotherapy (5 fluorouracil +/- oxaliplatin +/- irinotecan) +/- targeted therapy (cetuximab or panitumumab or bevacizumab) every 14 days * no prior chemotherapy for this adenocarcinoma with the exception of adjuvant chemotherapy * signed and dated informed consent document. exclusion criteria: * medical history of cancer within 5 years * medical contraindication for a treatment consisted of iv chemotherapy (5 fluorouracil +/- oxaliplatin +/- irinotecan) +/- targeted therapy (cetuximab or panitumumab or bevacizumab) * patient with known psychiatric or substance abuse disorders that could interfere with cooperation with the requirements of the study
effectiveness of noninvasive phrenic nerve neuromodulation in shoulder pain and hepatobiliary visceral comorbidity.

Conditions: Shoulder Pain

Summary: pain, particularly shoulder pain, is a social and economic problem worldwide. although visceral pathology is not yet taken into account in the diagnosis of these pains, it is likely that on numerous occasions the hepatobiliary visceral condition causes referred pain in the metameric area belonging to the shoulder due to the involvement of the phrenic nerve. therefore, the aim of this project is to study the response of treatment by neuromodulation of the phrenic nerve for shoulder pain in patients with associated hepatobiliary pathologies, assessing the possible visceral involvement in the symptomatology.

approximately 80% of patients with liver disease suffer chronic pain and fatigue, which can lead to sensitization of the central and peripheral nervous system. central sensitization is an increase in the responsiveness of neurons within the central nervous system, which can lead to generalized pain hypersensitivity. it has been shown that some lesions or inflammatory processes can trigger changes in the nervous system, generating persistent pain. according to the theory of visceral referred pain, there are visceral and musculoskeletal stimuli that converge in higher centers capable of producing referred pain in regions where metameric innervation is shared. this raises the possibility that altered visceral mechanisms may provoke and chronify musculoskeletal pain. according to this theory, people with structural or functional hepatobiliary pathologies may have referred pain in the right metameric territory of c2-c3-c4-c5, which may generate pain in the shoulder on the same side. this is due to the fact that the phrenic nerve sensitively innervates glisson's capsule, so any affectation of this structure can generate afferent stimuli to the previously mentioned metameric levels. the phrenic hypothesis plays a very important role today, having as its main "endorsement" the analgesic techniques of phrenic blockade used for shoulder pain after hepatectomy. in order to eliminate this post-operative shoulder pain, electrical or medical nerve blocks are used.

Eligibility criteria:
inclusion criteria: * over 18 years of age. * subjects presenting right shoulder pain at the time of enrollment in the study. * presentation of a hepatobiliary visceral disorder that may justify the visceral etiology of the pain. * that they agree to participate in the project by signing the informed consent form. exclusion criteria: * patients with chronic pain due to other diseases such as malignant disease. * patients with rheumatic diseases. * cutaneous infection in the area of pain. * disease of neurological, traumatic, oncologic, or infectious origin that rules out the visceral origin of the pain. * uncooperative subject. * severe psychiatric disease. * loss of cognitive capacity. * contraindication to electrotherapy.

Keywords: phrenic nerve shoulder pain nuromodulation
c reactive protein (crp) intervention to reduce inappropriate antibiotic prescriptions in the primary healthcare setting

Conditions: Acute Respiratory Infections

Summary: many studies have showed that rapid point-of-care (poc) c-reactive protein (crp) test can reduce inappropriate use of antibiotic at primary health care level. in vietnam, prevalence of antibiotic abuse for community acute respiratory infection has been reported. this study will test the hypothesis that crp poc testing for patients with non-severe acute respiratory illness at primary healthcare stations reduces inappropriate antibiotic use safely. the study will be conducted at ten district health care facilities in hanoi, viet nam. investigators intend to enroll 2,000 participants aged 6-65 years with non-severe acute respiratory infection. patients will be randomly allocated to the control or the intervention arm. participants in the control group will be treated according to routine care. participants in the intervention arm will have a crp test, the results of which will be available to the health care practitioner to contribute to their diagnosis and treatment decisions. all patients will be followed-up via telephone call after 14 days. the study will compare the proportion of patients in each arm receiving any antibiotics within 2 weeks of study enrollment.


Eligibility criteria:
inclusion criteria: * patients, aged 6 to 65 years, that visit one of the 10 selected primary healthcare centers * suspected to have acute respiratory tract infection (ari) by treating physician * informed consent exclusion criteria: * severe respiratory disease as determined by treating doctor * any disease or symptom requiring hospital referral as determined by treating doctor * immunosuppressed patients (e.g. hiv, long term steroid use) * suspicion of tuberculosis * evidence of acute or chronic liver disease (e.g. hepatitis or cirrhosis due to any cause) * past medical history of: neoplastic disease, congestive cardiac failure, chronic obstructive pulmonary disease, insulin-dependent diabetes or renal disease * pregnancy * no access to telephone * not able to come for follow up visit on day 3 or 4. * already taking antibiotics at the time of presentation * symptoms present for more than 2 weeks * presence of any sign of severe diseases as defined by the british thoracic society modified crp-65 system for severity scoring of pneumonia in primary care. for children (age ≥ 6 years and \< 16 years) additional exclusion criteria include: tachypnea, signs of chest wall in drawing, reduced consciousness, confusion, dehydration, hypothermia, severe malnutrition, unable to feed or drink, vomiting, and convulsions.
hyperalgesia in methadone-maintained patients: can it be treated?

Conditions: Opioid-Induced Hyperalgesia

Summary: utilizing a double-blind, placebo-controlled design, the proposed work will evaluate the ability of an adjuvant anticonvulsant analgesic to diminish or reverse the opioid-induced hyperalgesia complicating the pain states suffered by methadone-maintained (mm) patients. specifically, in a sample of mm patients, gabapentin, which has proven efficacy in treating neuropathic pain will be evaluated for its ability to ameliorate or diminish the opioid-induced hyperalgesia in these patients as reflected by changes on pain threshold and tolerance to both cold-pressor and electrical pain, at peak and through methadone blood levels. the results of this work will not only provide pharmacologic insight into the mechanisms underlying poor pain tolerance in this at-risk population, but also direction for the medical management of pain complicated by opioid-induced hyperalgesia.


Eligibility criteria:
inclusion criteria: potential participants must: 1. be between the ages of 21 and 55 years of age. 2. dsm-ivr diagnosis of prescription opioid abuse or dependence disorder 3. be compliant in methadone treatment 4. on a stable dose of methadone at least 6 weeks. 5. have provided random urine samples absent of any non-prescribed drugs of abuse x 2 months 6. be in good physical health or in the case of a medical condition needing ongoing treatment, be in the care of a physician who is willing to take responsibility for such treatment. the same conditions apply in cases of patients with a psychiatric disorder needing ongoing treatment. 7. be agreeable to and capable of signing an informed consent. exclusion criteria: potential participants must not: 1. have known sensitivity to gabapentin. 2. be substance dependent on alcohol, benzodiazepine, methamphetamine, cocaine or other drugs of abuse (except nicotine). 3. have any acute medical condition that would make participation medically hazardous, (e.g., acute hepatitis, unstable cardiovascular disease, liver or renal disease) or have liver enzyme values (ast or alt) greater than 5 times normal range. 4. be acutely psychotic, severely depressed and in need of inpatient treatment, or an immediate suicide risk. 5. have a neurological or psychiatric illness (i.e., schizophrenia, raynaud's disease, urticaria, stroke) that would affect pain responses. 6. be currently taking opioid analgesic medication for a painful condition on a regular basis. 7. be a nursing or pregnant female. female of childbearing potential must agree to use a medically acceptable method of birth control, (e.g. oral contraceptives, barrier (diaphragm or condom) with or without spermicide, levonorgestrel implant, intra-uterine progesterone contraceptives system, medroxyprogesterone acetate contraceptive injection) or to complete abstinence. females who become pregnant during the course of the study will be dropped from the study. 8. have a current or past history of high blood pressure, heart disease, stroke or currently have a pacemaker.

Keywords: opioid-induced hyperalgesia methadone gabapentin opioid addiction
local infiltration with ropivacaine improves postoperative pain control in patients

Conditions: Postoperative Pain

Summary: the purpose of this study is to evaluate the effect of pain relief after infusion of ropivacaine at port sites at end of laparoscopic cholecystectomy (lc)compared with placebo (0.9% normal saline).

patients were randomly assigned to two groups, on day 1,each subject was to undergo laparoscopic cholecystectomy under general anesthesia. anesthesia will be induced with fentanly (2-4ug/kg), propofol tci (4ug/ml), rocuronium (0.6mg/kg), and maintaine with remifentanly(0.1-0.3ug/kg.h) , and propofol tci (3-5ug/ml). at the end of the operation before wound closure, patients were randomized 1:1 to receive ropivacaine or placebo. in study group all wounds were infiltrated with 0.75% ropivacaine 14ml at port sites before wound closure(6ml for epigastric port ,6ml for umbilical port ,and 4ml for working port) . the study drugs will be applied to the skin, subcutis, fascia, and parietal peritoneum through the port sites at the end of surgery. all anesthetics will be stopped when wound infiltration completed. patients will be send to pacu for monitor a while then back to ward. record of pain intensity evaluation and rescue analgesic medication consumption were to continue through 48hours after administration of study drug. pain intensity will be assessed by using a 0-10 point vas scale. vas-rest and vas-coughing were recorded at the baseline ,2,4,6,8,12,18,24,48 hours. postoperative rescue analgesia consisit of parecoxib sodium 40mg be given by a nurse on requst of the subject to a maximum of 80mg per day.

Eligibility criteria:
inclusion criteria: * female or male, and any race, age≥18 years at the screening visite. * asa physical status i to ii. * scheduled to undergo laparoscopic cholecystectomy under general anesthesia. * famale subjects must be without pregnancy. * ability to provide informed consent, adhere to the study visite schedule, and complete all study assessments. exclusion criteria: * boss mass index \>35kg/㎡ * under intravertebral anesthesia and/or epidural analgesia * under postoperatived patient-controlled epidural analgesia (pcea) and postoperative intravenous analgesia(pcia). * inability to understand and use the visual analog scale (vas) * currently pregnant,nursing,or planning to become pregnant during the study or within one month after study drug administration. * chronic user of analgesic medications, including taking opioid medications for more than 14 days in the last 3months,or non-opioid pain medications more than 5 times per week. * proven or suspected allergy to local anesthetics ,nsaids and opioids . * use of any nsaids including selective cox-2 inhibitor , opioids or other analgesic agents within 3days of surgery. * history of suspected or known addiction to or abuse of drugs or alcohol within the past 2 years. * current acute or chronic medical or major psychiatric disease that,in the opinion of the investigator ,would interfere with the evaluation of study drug efficacy or safety. * any other subjects were not suitable to this study in the opinion of the investigator.